CN104159575B - 莫达非尼在治疗可卡因成瘾者中的应用 - Google Patents

莫达非尼在治疗可卡因成瘾者中的应用 Download PDF

Info

Publication number
CN104159575B
CN104159575B CN201380011342.7A CN201380011342A CN104159575B CN 104159575 B CN104159575 B CN 104159575B CN 201380011342 A CN201380011342 A CN 201380011342A CN 104159575 B CN104159575 B CN 104159575B
Authority
CN
China
Prior art keywords
modafinil
cocaine
less
pharmaceutical composition
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380011342.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104159575A (zh
Inventor
帕斯卡·祖普利
菲利浦·维维特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
D & A Pharmaceuticals
Original Assignee
D & A Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by D & A Pharmaceuticals filed Critical D & A Pharmaceuticals
Publication of CN104159575A publication Critical patent/CN104159575A/zh
Application granted granted Critical
Publication of CN104159575B publication Critical patent/CN104159575B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201380011342.7A 2012-02-28 2013-02-25 莫达非尼在治疗可卡因成瘾者中的应用 Expired - Fee Related CN104159575B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR12/00581 2012-02-28
FR1200581A FR2987267B1 (fr) 2012-02-28 2012-02-28 Application du modafinil dans le traitement de substitution des cacainomanes
PCT/FR2013/000052 WO2013128088A1 (fr) 2012-02-28 2013-02-25 Application du modafinil dans le traitement des cocaïnomanes

Publications (2)

Publication Number Publication Date
CN104159575A CN104159575A (zh) 2014-11-19
CN104159575B true CN104159575B (zh) 2018-09-04

Family

ID=48083447

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380011342.7A Expired - Fee Related CN104159575B (zh) 2012-02-28 2013-02-25 莫达非尼在治疗可卡因成瘾者中的应用

Country Status (33)

Country Link
US (1) US20150073055A1 (enExample)
EP (1) EP2819655B1 (enExample)
JP (1) JP6163169B2 (enExample)
KR (1) KR101897855B1 (enExample)
CN (1) CN104159575B (enExample)
AR (1) AR090169A1 (enExample)
AU (1) AU2013224831B2 (enExample)
BR (1) BR112014020626A2 (enExample)
CA (1) CA2863159C (enExample)
CL (1) CL2014002203A1 (enExample)
CY (1) CY1118166T1 (enExample)
DK (1) DK2819655T3 (enExample)
EA (1) EA025692B1 (enExample)
ES (1) ES2593276T3 (enExample)
FR (1) FR2987267B1 (enExample)
HR (1) HRP20161165T1 (enExample)
HU (1) HUE030737T2 (enExample)
IL (1) IL234009B (enExample)
IN (1) IN2014DN07831A (enExample)
LT (1) LT2819655T (enExample)
MX (1) MX348222B (enExample)
NZ (1) NZ628009A (enExample)
PH (1) PH12014501837A1 (enExample)
PL (1) PL2819655T3 (enExample)
PT (1) PT2819655T (enExample)
RS (1) RS55238B1 (enExample)
SG (1) SG11201405316WA (enExample)
SI (1) SI2819655T1 (enExample)
SM (1) SMT201600363B (enExample)
TW (1) TWI626042B (enExample)
UA (1) UA113301C2 (enExample)
WO (1) WO2013128088A1 (enExample)
ZA (1) ZA201405910B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105055404B (zh) * 2015-08-19 2017-07-18 四川大学 Hmgcs2抑制剂在制备治疗可卡因成瘾的药物中的用途
CN105055412B (zh) * 2015-08-20 2018-06-19 四川大学 Nampt抑制剂在制备治疗可卡因成瘾的药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123545A1 (en) * 2005-07-21 2009-05-14 Ron Eyal S Rapid Onset and Short Term Modafinil Compositions and Methods of Use Thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
FR2771004B1 (fr) 1997-11-19 2000-02-18 Inst Curie Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse
US20010034373A1 (en) 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
BR0114814A (pt) * 2000-10-11 2005-01-25 Cephalon Inc Composições compreendendo composto de modafinila e seu uso
US20040006532A1 (en) 2001-03-20 2004-01-08 David Lawrence Network access risk management
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
US7093476B2 (en) 2004-09-15 2006-08-22 Ut-Battelle, Llc Method for fabricating thin californium-containing radioactive source wires
CA2657409A1 (en) * 2006-07-12 2008-01-17 Elan Corporation, Plc Nanoparticulate formulations of modafinil
EP1980240A1 (en) * 2007-04-11 2008-10-15 Cephalon France Lyophilized pharmaceutical compositions and methods of making and using same
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123545A1 (en) * 2005-07-21 2009-05-14 Ron Eyal S Rapid Onset and Short Term Modafinil Compositions and Methods of Use Thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Formation of polymer particles with supercritical fluids: A review;Sang-Do Yeo etal;《The Journal of Supercritical Fluids》;20051231;第34卷;第287-308页 *
Modafinil for the treatment of cocaine dependence;Ann L. Anderson etal;《Drug and Alcohol Dependence》;20090626;第104卷;第133-139页 *

Also Published As

Publication number Publication date
WO2013128088A1 (fr) 2013-09-06
ES2593276T3 (es) 2016-12-07
UA113301C2 (xx) 2017-01-10
CN104159575A (zh) 2014-11-19
ZA201405910B (en) 2017-04-26
AU2013224831A1 (en) 2014-08-21
JP6163169B2 (ja) 2017-07-12
IL234009A0 (en) 2014-09-30
LT2819655T (lt) 2016-10-25
TW201340964A (zh) 2013-10-16
BR112014020626A2 (pt) 2017-06-27
SI2819655T1 (sl) 2016-11-30
KR101897855B1 (ko) 2018-09-12
KR20140135162A (ko) 2014-11-25
PH12014501837A1 (en) 2014-11-10
FR2987267B1 (fr) 2015-01-16
US20150073055A1 (en) 2015-03-12
AU2013224831B2 (en) 2017-05-11
HRP20161165T1 (hr) 2016-11-04
EP2819655B1 (fr) 2016-07-27
PL2819655T3 (pl) 2017-01-31
IN2014DN07831A (enExample) 2015-04-24
MX348222B (es) 2017-06-05
MX2014010237A (es) 2015-07-17
CL2014002203A1 (es) 2015-04-10
WO2013128088A8 (fr) 2014-09-12
TWI626042B (zh) 2018-06-11
CA2863159A1 (fr) 2013-09-06
EA201400960A1 (ru) 2014-12-30
AR090169A1 (es) 2014-10-22
DK2819655T3 (en) 2016-11-28
HUE030737T2 (en) 2017-05-29
NZ628009A (en) 2015-07-31
FR2987267A1 (fr) 2013-08-30
IL234009B (en) 2018-01-31
PT2819655T (pt) 2016-10-14
CY1118166T1 (el) 2017-06-28
EP2819655A1 (fr) 2015-01-07
RS55238B1 (sr) 2017-02-28
JP2015508805A (ja) 2015-03-23
CA2863159C (fr) 2018-06-12
SMT201600363B (it) 2016-11-10
SG11201405316WA (en) 2014-11-27
EA025692B1 (ru) 2017-01-30

Similar Documents

Publication Publication Date Title
KR101834033B1 (ko) 주의력 결핍 장애 치료용 고체 경구 제약 조성물
ES2753141T3 (es) Formulación de liberación modificada de lacosamida
EP3481385B1 (en) Pulsatile drug delivery system for treating morning akinesia
JP2012514632A (ja) 二段階放出型医薬懸濁剤
CN114340670A (zh) T-型钙通道调节剂的制剂及其使用方法
BR112014025907B1 (pt) Formulação farmacêutica disponível para administração por via oral adequada para manejo aprimorado de transtornos do movimento
JP2007509146A (ja) レボドーパの持続効果のための組成物及び投与形
CN111328282A (zh) 加波沙朵在治疗发作性睡病中的用途
EP3733167A1 (en) Novel fine particle coating (drug-containing hollow particle and method for manufacturing same)
CN104159575B (zh) 莫达非尼在治疗可卡因成瘾者中的应用
CN102429905B (zh) 一种含有延胡索乙素和欧前胡素的药物组合物
KR101473998B1 (ko) 에페리손 함유 필름코팅정제
JP2022511755A (ja) 精神障害の治療のためのガボキサドールとリチウムとの組み合わせ
KR102090784B1 (ko) 빠른 용출률을 나타내는 아토목세틴을 포함하는 경구용 약학 제제 및 이의 제조방법
EP3628316A1 (en) Multivitamin composition for improving verbal fluency, decreasing performance anxiety symptoms and method for preparing same
Sampathkumar et al. Gastric Floating Microcapsules for the Management of Parkinson’s Disease
KR101151342B1 (ko) 에페리손 함유 필름코팅정제, 및 이의 제조방법
CN120983432A (zh) 烟碱和第二代抗精神病药联合在制备缓解双相抑郁药物中的应用
HK40065529A (en) Combination of gaboxadol and lithium for the treatment of psychiatric disorders
KR20130106023A (ko) 에페리손 함유 필름코팅정제, 및 이의 제조방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180904

Termination date: 20200225